Journals / Viral Hepatitis Journal / 2012 / Cilt: 18 - Sayı: 2

Antibody Response to Hepatitis B Vaccination in Isolated Anti-Hbc IgG Positive Cases

İzole Anti-HBc IgG Pozitif Olan Olgularda Hepatit B Aşılamasına Karşı Gelişen Antikor Yanıtı

Pages
71–75
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

But we need further studies involving more people.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We aimed to investigate the antibody response secondary to 1 dose of hepatitis B vaccine and factors affecting this response in isolated cases of anti-HBc IgG positive cases.
📊
Key Findings & Data:The level of anti-HBs was measured at the 10th and 30th day after the administration of hepatitis B vaccine to these 41 people.
💡
Conclusion & Impact:But we need further studies involving more people.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: We aimed to investigate the antibody response secondary to 1 dose of hepatitis B vaccine and factors affecting this response in isolated cases of anti-HBc IgG positive cases. Materials and Methods: Fortyone people who were positive for isolated anti-HBc and negative for other markers of hepatitis B were recruited in the study. The level of anti-HBs was measured at the 10th and 30th day after the administration of hepatitis B vaccine to these 41 people. HBV-DNA was searched with PCR in people who did not developed a secondary antibody response to one dose of vaccination at Day 10 and 30. Results: Anti-HBs was found to be at protective levels (&#8805; 10 IU/mL) in 27 (65.8 %) out of 41 people included in the study. The antibody response developed in 27 people with one dose of vaccination was thought to be a secondary response, and the 14 people who did not form anti-HBs and were found to be negative for HBV- DNA by PCR were thought to have false anti-HBc positivity and be inactive HBs Ag carriers (HBs Ag falling below the measurable level in time and presence of anti- HBe or preS, S, precor, cor mutant strain infection). There was a highly significant correlation between antibody levels at Day 10 and Day 30 (p<0.001). In addition, when the antibody levels of people who developed secondary response at Day 10 were investigated, antibody levels of non-smokers were found to be (0-1000 IU/mL; 194.3±327.2 IU/mL) significantly higher compared to smokers (0-70 IU/mL; 12± 21.8 IU/mL) (p=0.015). No statistically significant difference was determined between the antibody responses at Day 10 and Day 30 of people with a history of diabetes mellitus (DM), malignity, chronic diseases, alcohol consumption, previous HBsAg positivity and HBV-DNA positivity, anti-HCV positivity, and hepatitis B carriers in the family (p>0.05). Conclusion: An anamnestic response is suggested in people who give anti-HBs response to one dose of hepatitis B vaccine. However, a false anti-HBc IgG positivity or undetectable levels of HBs Ag should be considered in people who do not give antibody response. According to our results smoking affects the level of antibody response negatively. But we need further studies involving more people.

Özet

Amaç: İzole anti-HBc IgG pozitif olan kişilerde 1 doz hepatit B aşısı ile sekonder antikor yanıtını ve bu yanıtı etkileyen faktörleri araştırmayı amaçladık. Gereç ve Yöntemler: Çalışmaya izole anti-HBc IgG pozitif, diğer hepatit B belirteçleri negatif olan 41 kişi alındı. Kırkbir kişiye hepatit B aşısı uygulandıktan sonra 10-30. günlerde anti-HBs düzeyi ölçüldü. Bir doz aşıdan sonra 10. ve 30. günlerde sekonder antikor yanıtı gelişmeyen kişilerde PCR ile HBV-DNA bakıldı. İzole anti-HBc IgG pozitifliği olan hastalarda altta yatan hastalıkları, alkol kullanımı, sigara kullanımı (en az 5 yıl, günde 10 tane sigaradan fazla içen hastalar) irdelendi. Bulgular: Çalışmaya alınan 41 kişiden 27’sinde (%65,8) 1 doz aşı sonrası anti- HBs koruyucu düzeyde (≥10IU/mL) ölçüldü. Bir doz aşı ile 27 kişide gelişen antikor yanıtının sekonder yanıt olduğu, anti-HBs oluşmayan ve PCR ile HBV- DNA negatif olan 14 kişinin yalancı anti-HBc pozitifliği veya inaktif HBs taşıyıcısı (zamanla ölçülebilir düzeyin altına düşen HBs Ag ve anti-HBs varlığı) veya preS, S, precor, cor mutant suş enfeksiyonu olabileceği düşünüldü. Sekonder yanıtı hem onuncu gün, hem 30.gün bakılabilen hastalarda 10. gün antikor yanıt düzeyleri ile 30. gün antikor düzeyleri arasında ileri derecede anlamlı korelasyon mevcuttu (p 0,05). Sonuç: Bir doz hepatit B aşısı ile anti-HBs yanıtı alınan kişilerde anamnestik yanıt olduğu düşünülmektedir. Antikor yanıtı gelişmeyenlerde ise yalancı pozitiflik ya da saptanamayan düzeyde HBs Ag düşünülmelidir. Çalışmamızın sonuçlarına göre sigaranın anamnestik antikor yanıt düzeyi üzerinde etkisi bulunmaktadır. Ancak çalışmada değerlendirilen hasta sayısının az olması nedeni ile bu konuda kesin sonuca ulaşmak için daha fazla sayıda hasta içeren çalışmalara ihtiyaç vardır.

🔖

Cite This Article

KAZAK, E., YILMAZ, E., MISTIK, R., AKALIN, H., AKGÖZ, S., GÖRAL, G. (2012). Antibody Response to Hepatitis B Vaccination in Isolated Anti-Hbc IgG Positive Cases. Viral Hepatitis Journal, Cilt: 18 - Sayı: 2, 71–75. https://ajindex.com/articles/332783

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ural O, Fındık D. The response of isolated anti-HBc positive subjects to recombinant hepatitis B vaccine. Journal of Infect. 2001; 43: 187-90
  2. Draelos M, Morgan T, Schifman RB, Sampliner RE. Significance of isolated antibody to hepatitis B core antigen determined by immune response to hepatitis B vaccination. JAMA. 1987; 258: 1193-5
  3. Gandhi RT, Wurcel A, Lee H, McGoven B, Shopis J, Geary M, et al. Response to hepatitis B vaccine in HIV-1 positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis. 2005; 191: 1435-41
  4. Almeida Neto C, Strauss E, Sabino EC, Sucupira MC, Chamone DA. Significance of isolated hepatitis B core antibody in blood donors from Sao Paulo. Rev Inst Med Trop Sao Paulo. 2001; 43: 203-8
  5. Kabir A, Keshvari M, Kashani AHF, Alavian SM. Predicting response to HBV vaccination in people with positive anti-HBc but negative HBsAg and anti-HBs. Human Vaccin. 2008; 4: 379-83
  6. Özacar T, Zeytinoğlu A, Erensoy S, Yapar A, Hoşgör M, Bilgiç A. Hepatit B virus serolojisinde salt antiHBc olumluluğu ve HBV aşısına yanıt. Viral Hepatit Derg 1995; 2: 69-71
  7. Sünbül M, Leblebicioglu H, Esen S, Eroglu C, Barut S. Response to hepatitis B vaccine in HBsAg/anti-HBs negative and anti-HBc positive subjects. Scand J Infect Dis. 2000; 32: 315-6
  8. Alhababi F, Sallam TA, Tong CY. The significance of ’anti-HBc only’ in the clinical virology laboratory. J Clin Virol. 2003; 27: 162-9
  9. Grob P, Jilg W, Bornhak H, Gerken G, Gerlich W, Günther S, et al. Serological pattern “Anti-HBc alone”:Report on a workshop. J Med Virol. 2000; 62: 450-5
  10. Silva AE, McMahon BJ, Parkinson AJ, Sjongren MH, Hoofnagle JH, Di Bisceglie AM. Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. CIin Infect Dis. 1998; 26: 895-7
  11. Behzad-Behbahani A, Mafi-Nejad A, Tabie SZ, Lankarani KB, Torab A, Moaddeb A. Anti-HBc & HBV-DNA detection in blood donors negative for hepatitis B virus surface antigen in reducing risk of transfusion associated HBV infection. Indian J Med Res.2006; 123: 37-42
  12. Weber B, Melchior W, Gehrke R, Doerr HW, Berger A, Rabenau H. Hepatitis B virus markers in anti-HBc only positive individuals. J Med Virol. 2001; 64: 312-9
  13. Berger A, Doerr HW, Rabenau HF, Weber B. High frequency of HCV infection in individuals with isolated antibody to hepatitis B core antigen. Intervirology. 200